Cosmos Health reports H1 2023 adjusted net income $3.01M, issues 2026 guidance of $180M revenue

Cosmos Health Inc.

H1 2023 Adjusted EBITDA of $3.01M (up 182% YoY) and Adjusted Net Income of $3.01M (up from -$0.09M loss).
Inaugural 2026 guidance: gross annual revenue exceeding $180M and EBITDA >$20M.
Completed three acquisitions in 2023: Cana Laboratories, Bikas GP (adds >$10M annual revenue), and ZipDoctor.
Book value per share >$4 (2.5x current price); unencumbered properties fair value >$12M (>50% market cap).
CEO Greg Siokas invested >$15M total, ~$850K YTD; share buyback up to $3M started Sept 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.